Integrating New Type 2 Diabetes Algorithms into Clinical Practice: Applying AACE Guidelines to Complex Patients with Diabetes
Diabetes is a growing epidemic in the United States, affecting an estimated 29.1 million individuals or 9.3% of the population, with type 2 diabetes (T2D) accounting for up to 95% of all cases.[CDC 2014] Without appropriate glycemic control, T2D is associated with significant morbidity and mortality.[ADA 2016] Despite the availability of effective treatment options, 46.5% of patients with T2D fail to achieve the American Diabetes Association (ADA)-recommended glycated hemoglobin (A1c) goal of <7.0%.
The goal of this activity is to increase awareness of the updated 2017 American Association of Clinical Endocrinologists/American College of Endocrinology consensus statement on the comprehensive treatment of T2D and use it to develop individualized patient care plans.
Please Note: this course is housed on Medscape. Upon selecting 'Take Course,' you will be redirected to Medscape to compete the activity.
This activity is intended for diabetologists and endocrinologists, primary care physicians, and cardiologists who treat patients with type 2 diabetes (T2D).
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the updated guideline recommendations for T2D treatment
- Have greater competence related to individualize treatment strategies for complex patients with T2D
Janet McGill, MD, MA, FACE
Associate Professor of Medicine, Division of Endocrinology, Metabolism, and Lipid Research. Washington University, St. Louis, Missouri
Disclosure: Janet McGill, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer-Ingelheim Pharmaceuticals, Inc.; Dexcom, Inc.; Dynavax Technologies Corporation; Intarcia Therapeutics, Inc.; Merck & Co., Inc.; Novo Nordisk; Valeritas, Inc
Served as a speaker or a member of a speakers bureau for: Dexcom, Inc.; Janssen Pharmaceuticals, Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP/Bristol-Myers Squibb Company; Dexcom, Inc.; Lexicon Pharmaceuticals, Inc./Sanofi; Novartis Pharmaceuticals Corporation
Dr. McGill does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr. McGill does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA
- 1.00 Attendance